Indian Glivec case rescheduled for July
This article was originally published in Scrip
Executive Summary
The crucial Indian patent case concerning Novartis' anticancer Glivec (imatinib mesylate) and its rejection due to Section 3(d), a controversial provision in India's patent law, will now be heard in July.